Update in ITP and TTP SPOC

Immune Thrombocytopenic Purpura and Thrombotic Thrombocytopenic Purpura are both autoimmune conditions leading to low platelets, though the mechanism by which the platelets are consumed differs.  The lecture will update viewers on new therapies for the treatment of ITP and TTP

Target Audience

These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, and others who are interested in care of patients with cancer in North Carolina.

Learning Objectives

  • Explain the role of thrombopoietin receptor agonists in the treatment of ITP
  • Discuss the role of caplacizumab in the treatment of TTP
  • Describe the optimal prophylaxis and immunizations for patients treated with prolonged corticosteroids or other immunosuppressants for ITP and TTP
Course summary
Available credit: 
  • 1.00 Participation

    UNC Lineberger Cancer Network certificate of participation.

    Tim Poe, Director of Telehealth

Course opens: 
04/14/2021
Course expires: 
12/31/2027
Rating: 
0
Photo of Alice Ma, MD, FACP 

Alice Ma, MD, FACP

Fellow
The Medical Alumni Loyalty Fund Distinguished Teaching Professor
Director, Division of Hematology Fellowship
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

 

Presenter Disclosure Information

Alice Ma, MD, FACP, has no relevant financial relationships with commercial interests as defined by the ACCME.

 

This Non-Credit Course does not have accreditation. It only offers general participation certificates.

Available Credit

  • 1.00 Participation

    UNC Lineberger Cancer Network certificate of participation.

    Tim Poe, Director of Telehealth

Please login or register to take this course.